Immunovant Q3 net loss $110.6 million, or $0.61 per share; cash $994.5 million
Immunovant reported results for the fiscal third quarter ended December 31, 2025, with a net loss of $110.6 million ($0.61 per share), compared with $111.1 million ($0.76 per share) a year earlier. Cash and cash equivalents were $994.5 million at December 31, 2025, following a December 2025 underwritten financing with institutional investors and Roivant that generated approximately $550 million in gross proceeds, which the company says extends its cash runway to the potential launch of IMVT-1402 in Graves' disease.
Key points
- Q3 net loss was $110.6 million ($0.61 per share), versus $111.1 million ($0.76 per share) in the prior-year quarter.
- R&D expenses rose to $98.9 million from $94.5 million, driven by IMVT-1402 trial activities, including contract manufacturing costs.
- G&A expenses fell to $15.4 million from $19.8 million, mainly due to lower personnel-related expenses, market research and IT costs.
- The December 2025 financing generated approximately $550 million in gross proceeds; shares outstanding were 203,316,885 at December 31, 2025.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.